Therapeutic Targets Database
BIDD Pharmainformatics Databases


TTD Drug ID: DAP000184

Drug Information
SynonymsMLS000084585; C07263; CHEMBL57; MLS001055309; 11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[2,3-e:3',2'-b][1,4]diazepin-6-one & PRO 140 (Anti-CCR5 monoclonal antibody); HMS2051J09; NCGC00065890-02; CPD000048458; BIRG-0587; Nevirapine & PRO 140; 1vrt; 129618-40-2; SAM001246551; 11-Cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido(3,2-b:2',3'-e)(1,4)diazepin-6-one; HSDB 7164; BI RG 587; STK580320; BI-RG-587; DB08311; N11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e]-[1,4]diazepin-6-one & CD4-immunoadhesin; BIDD:GT0326; MLS000759409; UNII-99DK7FVK1H; NVP; NON-NUCLEOSIDE RT INHIBITOR NEVIRAPINE; NEV; Nevirapine (JAN/USP/INN); D00435; BI-RG-587 & CD4-IgG; NSC641530; S1742_Selleck; Cahill May Roberts Brand of Nevirapine; SMR000048458; BIRG-587; Promeco Brand of Nevirapine; BIRG587; DB00238; I02-0310; 2hny; nevirapine; Viramune (TN); Bio-0789; 11-CYCLOPROPYL-5,11-DIHYDRO-4-METHYL-6H-DIPYRIDO[3,2-B:2',3'-E][1,4]DIAZEPIN-6-ONE; CHEBI:44659; 11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[2,3-e:3',2'-b][1,4]diazepin-6-one; LS-2289; CID4463; Viramune, BI-RG 587, Nevirapine; AC-643; 11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one; Viramune; BIRG 0587; C15H14N4O; ZINC00004778; 6H-Dipyrido(3,2-b:2',3'-e)(1,4)diazepin-6-one, 11-cyclopropyl-5,11-dihydro-4-methyl-; 5H-Dipyrido(3,2-b:2',3'-e)(1,4)diazepin-6-one, 5,11-dihydro-11-cyclopropyl-4-methyl-; D019829; Nevirapine & CD4-IgG; BIRG 587; Nevirapine [USAN:INN]; Viramune(TM); AC1L1I81; MolPort-002-507-817; MLS001201730; NSC 641530
Trade NameViramune
CompanyBoehringer Ingelheim
IndicationHIV infection
[ICD9: 042   ICD10: B20]
Approved    [1]

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
Canonical SMILESCC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4    
Therapeutic ClassAnti-HIV Agents
CAS NumberCAS 129618-40-2
PubChem Compound IDCID 4463.
PubChem Substance IDSID 9472.
SuperDrug ATC IDJ05AG01
SuperDrug CAS ID129618402;
TargetNonnucleoside reverse transcriptaseInhibitor[2][3][4]
Ref 1Approved antiretroviral drugs. 2009 To Reference
Ref 2The human immunodeficiency virus type 1 nonnucleoside reverse transcriptase inhibitor resistance mutation I132M confers hypersensitivity to nucleoside analogs. J Virol. 2009 Apr;83(8):3826-33. Epub 2009 Feb 4. To Reference
Ref 3Nevirapine Increases High-Density Lipoprotein Cholesterol Concentration by Stimulation of Apolipoprotein A-I Production. Arterioscler Thromb Vasc Biol. 2009 Aug 10. [Epub ahead of print] To Reference
Ref 4Mini Rev Med Chem. 2007 Nov;7(11):1108-19.Privileged structures: a useful concept for the rational design of new lead drug candidates. To Reference


Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.

Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore

All rights reserved.

Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links


Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543